title: Parkinson disease: Laying the foundations for disease-modifying therapies in PD.
abstract: The results of a futility trial, which used the PPAR-γ receptor agonist pioglitazone in an attempt to modify disease progression in Parkinson disease, do not support initiation of further trials. However, although this trial was well designed and conducted, we question whether it is time to fully shut the door on pioglitazone.
authors: Van Andel Research Institute, Translational Parkinson's Disease Research, Center for Neurodegenerative Science, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA.
authors: Patrik
authors: P
authors: Brundin
authors: The Cure Parkinson's Trust, 120 Baker Street, London W1U 6TU, UK.
authors: Richard
authors: R
authors: Wyse
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy*; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D018696:Neuroprotective Agents; D045162:Thiazolidinediones